| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/20/2002 | WO2001097780A3 Pharmaceutical compositions comprising an opioid analgesic |
| 06/20/2002 | WO2001090191A3 ANTIBODIES CAPABLE TO SELECTIVELY DETECT PRION PrPSc ISOFORMS |
| 06/20/2002 | WO2001090139A3 A ligand for enhancing oral and cns delivery of biological agents |
| 06/20/2002 | WO2001089570A3 Combination of growth hormone secretagogues and antidepressants |
| 06/20/2002 | WO2001088104A3 Neural progenitor cell populations |
| 06/20/2002 | WO2001085959A3 Regulation of human lysostaphin-like protease |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001083524A3 Rna metabolism proteins |
| 06/20/2002 | WO2001076576A3 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 06/20/2002 | WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 06/20/2002 | WO2001070231A3 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 06/20/2002 | WO2001068851A3 Polypeptides and nucleic acids encoding same |
| 06/20/2002 | WO2001068068A3 Compounds capable of binding with the cytoskeleton |
| 06/20/2002 | WO2001060857A3 Compositions useful for regulating parkin gene activity |
| 06/20/2002 | WO2001056590A3 Utilization of protein kinase inhibitor alpha |
| 06/20/2002 | WO2001054771A3 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/20/2002 | WO2001044445A8 Human lyases and associated proteins |
| 06/20/2002 | WO2001030328A3 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000077233A9 Complement-resistant non-mammalian dna viruses and uses thereof |
| 06/20/2002 | WO2000067734A3 Use of phthalazine derivatives |
| 06/20/2002 | WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 06/20/2002 | WO2000061596A8 50 human secreted proteins |
| 06/20/2002 | WO2000052210A9 Methods for targeting rna molecules |
| 06/20/2002 | US20020077468 Corticotropin-releasing factor2 receptors |
| 06/20/2002 | US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis |
| 06/20/2002 | US20020077362 Higher unsaturated fatty acid composition |
| 06/20/2002 | US20020077361 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 06/20/2002 | US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition |
| 06/20/2002 | US20020077356 Nonsteroidal antiinflammatory agents |
| 06/20/2002 | US20020077353 Reacting 1-(3-Dimethylamino-1-propyl)-1-(4-fluorophenyl)-5-((trifluoromethyl)sulfonyl-oxy)-1,3-dihydroisobenzofurane or 1-(4'-fluorophenyl)-1- (3-dimethylaminopropyl)-5-bromophtalane with with a cyanide source in presence of palladium catalyst |
| 06/20/2002 | US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation |
| 06/20/2002 | US20020077346 For therapy of inflammatory and pain of a traumatic or pathologic origin |
| 06/20/2002 | US20020077342 For use in therapy of epilepsy, depression, tension, gastrointestinal disorders, pain, inflammation |
| 06/20/2002 | US20020077339 Chemokine receptor binding heterocyclic compounds |
| 06/20/2002 | US20020077337 Chemical compounds |
| 06/20/2002 | US20020077334 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 06/20/2002 | US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2) |
| 06/20/2002 | US20020077332 Zolpidem hemitartrate |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077328 Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
| 06/20/2002 | US20020077326 (S)-hydroxynefazodone antipsychotic therapy |
| 06/20/2002 | US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them |
| 06/20/2002 | US20020077319 Combination of GABA agonists and aldose reductase inhibitors |
| 06/20/2002 | US20020077318 Substituted azepino[4,5b] indoline derivatives |
| 06/20/2002 | US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder |
| 06/20/2002 | US20020077304 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
| 06/20/2002 | US20020077295 For therapy of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease |
| 06/20/2002 | US20020077288 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
| 06/20/2002 | US20020077274 Administering therapeutically effective amount of a compound that inhibits cGMP-specific phosphodiesterase (PDE5) for therapy of Parkinson's disease |
| 06/20/2002 | US20020076800 Protein |
| 06/20/2002 | US20020076796 2786, a novel human aminopeptidase |
| 06/20/2002 | US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4 |
| 06/20/2002 | US20020076781 Regulation of intracellular glucocorticoid concentrations |
| 06/20/2002 | US20020076766 Novel glucosaminidase |
| 06/20/2002 | US20020076758 Polypeptide |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |
| 06/20/2002 | US20020076456 Compositions and methods of use for extracts of magnoliaceae plants |
| 06/20/2002 | US20020076446 Novel medicinal herbal composition for treating liver diseases and HIV |
| 06/20/2002 | US20020076421 Oral liquid mucoadhesive compositions |
| 06/20/2002 | US20020076418 Use of strains of parapoxvirus ovis against organ fibrosis |
| 06/20/2002 | US20020076399 Treatment of immune diseases |
| 06/20/2002 | DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane |
| 06/20/2002 | DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers |
| 06/20/2002 | DE10060807A1 Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen Ortho, ortho-substituted nitrogen-containing Bisarylverbindungen, processes for their preparation, their use as a medicine as well as pharmaceutical compositions containing them |
| 06/20/2002 | DE10060677A1 Klainetine und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben Klainetins and their derivatives, process for their preparation and use thereof |
| 06/20/2002 | CA2436830A1 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 06/20/2002 | CA2431406A1 Quinazolinone derivatives |
| 06/20/2002 | CA2431287A1 Method and apparatus for treating breakthrough pain |
| 06/20/2002 | CA2431172A1 Nmda receptor antagonist pharmaceutical compositions |
| 06/20/2002 | CA2430992A1 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 06/20/2002 | CA2430151A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| 06/20/2002 | CA2428216A1 Secreted proteins |
| 06/19/2002 | EP1215587A2 Adenosine monophosphate deaminase crystal structure |
| 06/19/2002 | EP1215497A1 Diagnostics for transmissible spongiform encephalopathy |
| 06/19/2002 | EP1215214A1 Novel polypeptide |
| 06/19/2002 | EP1215210A2 Benzofurans |
| 06/19/2002 | EP1214945A2 Method and medicament for inhibiting the expression of a defined gene |
| 06/19/2002 | EP1214944A1 Percutaneous absorption agents |
| 06/19/2002 | EP1214943A1 T-cell therapeutics for transmissible spongiform encephalopathy and method for the manufacture of non-infective blood products and tissue derived products |
| 06/19/2002 | EP1214599A2 Screening for alpha2delta-1 subunit binding ligands |
| 06/19/2002 | EP1214598A2 Screening for inhibitors of "paired helical filaments" |
| 06/19/2002 | EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 06/19/2002 | EP1214422A1 Phosphatases which activate map kinase pathways |
| 06/19/2002 | EP1214404A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 06/19/2002 | EP1214401A2 Dna encoding the human serine protease c-e |
| 06/19/2002 | EP1214400A2 Zymogen activation system |
| 06/19/2002 | EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 06/19/2002 | EP1214350A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 06/19/2002 | EP1214349A2 Secreted soluble alpha2delta-2, alpha2delta-3 or alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 06/19/2002 | EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 06/19/2002 | EP1214337A2 Proteins associated with cell differentiation |
| 06/19/2002 | EP1214335A1 Gamma-carboxyglutamate containing conopeptides |
| 06/19/2002 | EP1214325A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214324A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214322A2 Amino-triazolopyridine derivatives |
| 06/19/2002 | EP1214320A1 Pyrido-pyridazine derivatives as ligands for gaba receptors |
| 06/19/2002 | EP1214319A1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 06/19/2002 | EP1214313A2 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/19/2002 | EP1214312A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |